BioSpace News Archive

Nucleai, a spatial AI biomarker company that deciphers cellular conversations and maps cellular interactions within tissue samples to predict therapeutic outcomes, will showcase its developments in cancer research and diagnostics at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, California from April 5-10, 2024.

Novocure announced 20 presentations on Tumor Treating Fields therapy will be delivered at the American Association for Cancer Research Annual Meeting 2024, to be held April 5 to 10 in San Diego.

Biofidelity announced that new data from its breakthrough product ASPYRE-Lung will be presented in three scientific posters, including a Late Breaking Abstract (LBA), at the upcoming American Association for Cancer Research (AACR) 2024 Annual Meeting, April 5-10, in San Diego, CA.

Arcutis Biotherapeutics, Inc. reported the grant of an aggregate of 58,500 restricted stock units of Arcutis’ common stock to four newly hired employees.

23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human genetics and biopharmaceutical company, will present data on its two clinical stage programs, 23ME-01473 targeting ULBP6, and 23ME-00610 targeting CD200R1, at the American Association for Cancer Research (AACR) Annual Meeting 2024, taking place in San Diego, CA, April 5-10, 2024.

Atara Biotherapeutics, Inc. reported the grant of 3,750 restricted stock units of Atara’s common stock to one newly hired employee.

ORIC Pharmaceuticals, Inc. announced that on April 1, 2024, ORIC granted a total of 84,800 non-qualified stock options and 14,400 restricted stock units to two new non-executive employees who began their employment with ORIC in March 2024.

Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL) is presenting preclinical data on development candidates WTX-518 and WTX-712 in posters at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 5-10 in San Diego, California.

Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”) today announced that it will be sharing pipeline updates for all investigational candidates at the upcoming American Association for Cancer Research (“AACR”) Annual Meeting, taking place in San Diego, California from April 5-10, 2024.

Antengene Corporation Limited announced the presentation of four preclinical posters at the 2024 American Association for Cancer Research Annual Meeting, taking place from April 5th to April 10th at the San Diego Convention Center in San Diego, California, the United States.